Shame management didn't declare a dividend this half given cash position - even if at 1-1.5c - it would have helped with sp appreciation at least till going ex div and of course a few more dollars to holders would have been handy to help with living cost pressures. As it is, sp retreats but guessing mainly due to general market movement.
Management keeps hinting on addressing LOM issues but won't announce anything until something is firm, which is obviously fair enough, so in the interim it's a wait game and guess work at best as to what will happen exactly.
Good to know though that cash position should be even better by Q end, subject to IOP and the number and size of shipments. Unfortunately an end of year dividend (if any, as by then cash may be spent on a much anticipated acquisition) is still a long way away but sp will hopefully react positively (thus growth v dividends?) once path to growing resource becomes clearer.
- Forums
- ASX - By Stock
- FEX
- Ann: Half Yearly Report and Accounts
FEX
fenix resources ltd
Add to My Watchlist
1.75%
!
29.0¢

Ann: Half Yearly Report and Accounts, page-8
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
29.0¢ |
Change
0.005(1.75%) |
Mkt cap ! $214.9M |
Open | High | Low | Value | Volume |
28.5¢ | 29.0¢ | 28.0¢ | $352.1K | 1.236M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 3236 | 28.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
29.0¢ | 405153 | 12 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 3236 | 0.285 |
4 | 1008366 | 0.280 |
4 | 351241 | 0.275 |
12 | 340507 | 0.270 |
10 | 592464 | 0.265 |
Price($) | Vol. | No. |
---|---|---|
0.290 | 287092 | 11 |
0.295 | 126500 | 4 |
0.300 | 1959448 | 8 |
0.305 | 216675 | 3 |
0.310 | 657405 | 13 |
Last trade - 16.10pm 04/07/2025 (20 minute delay) ? |
Featured News
FEX (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online